| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000040490 |
| Receipt No. | R000045914 |
| Scientific Title | Effects of Fermented Kochi Golden Ginger Powder and Kochi Red Ginger Powder on Skin Surface Temperature |
| Date of disclosure of the study information | 2021/05/15 |
| Last modified on | 2020/11/11 (Ver. 3) |
| Basic information | ||
| Public title | Effects of Fermented Kochi Golden Ginger Powder and Kochi Red Ginger Powder on Skin Surface Temperature | |
| Acronym | Effects of Fermented Kochi Golden Ginger Powder and Kochi Red Ginger Powder on Skin Surface Temperature | |
| Scientific Title | Effects of Fermented Kochi Golden Ginger Powder and Kochi Red Ginger Powder on Skin Surface Temperature | |
| Scientific Title:Acronym | Effects of Fermented Kochi Golden Ginger Powder and Kochi Red Ginger Powder on Skin Surface Temperature | |
| Region |
|
|
| Condition | ||
| Condition | N/A (healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study examines the effects of the test food on peripheral blood flow and skin surface temperature. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Peripheral blood flow and skin surface temperature |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake the test food 1 for 1 week | |
| Interventions/Control_2 | Intake the test food 2 for 1 week | |
| Interventions/Control_3 | Intake the control food for 1 week | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1)Healthy Japanese females aged 20-64 years
2)Those who are sensitive to cold 3)Those whose written informed consent has been obtained |
|||
| Key exclusion criteria | 1)Those who have a history of diabetes, liver disease, kidney disease, digestive system disease, heart disease, or other diseases that may affect the results of this test, or who have had a history of surgery
2)Those with abnormal liver and renal function test values 3)Those who have a disease currently being treated 4)Those with food and drug allergies 5)Those who play intense sports and who are on a diet 6)Those who routinely use internal medicines (including foods and supplements) and skin medicines (applications, patches, sprays, etc.) that are expected to have health-promoting effects on skin tissues and blood / vascular functions 7)Those who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and designated quasi-drugs during the test period 8)Those who continuously take medicines (including OTC and prescription medicines) 9)Those who routinely perform various therapies (esthetic treatment, massage, etc.) that are expected to have health-promoting effects on skin tissue and blood / vascular functions 10)Those with a marked abnormality in the skin condition at the test site or those with chronic skin symptoms such as atopic dermatitis 11)Heavy drinkers, or those who can't stop drinking from the day before the test until the day 12)Those with irregular life patterns and with lifestyle of reversal of day and night 13)Those who have habits of excessive eating and drinking 14)Those who have been pregnant or those who have a plan to become pregnant or breast feed during the study period 15)Those who are participating in or will be participating in other clinical trials at the start of this study, and those within 4 weeks after the end 16)Those who judged that examination responsible doctor is not appropriate for this study participation |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Ryusendo Co., Ltd. | ||||||
| Division name | President and CEO | ||||||
| Zip code | 171-0021 | ||||||
| Address | 1-5-3 Nishi-ikebukuro, Toshima-ku, Tokyo 171-0021, Japan | ||||||
| TEL | 03-3985-8346 | ||||||
| y.shiojima@ryusendo.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Ryusendo Co., Ltd. | ||||||
| Division name | Development Division | ||||||
| Zip code | 171-0021 | ||||||
| Address | 1-5-3 Nishi-ikebukuro, Toshima-ku, Tokyo 171-0021, Japan | ||||||
| TEL | 03-3985-8346 | ||||||
| Homepage URL | |||||||
| m.takahashi@ryusendo.co.jp | |||||||
| Sponsor | |
| Institute | Oneness support Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ryusendo Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | Sakata Nobuo Corporation
Ishokukenbi Co., Ltd. |
| IRB Contact (For public release) | |
| Organization | Miura Clinic, Medical Corporation Kanonkai IRB |
| Address | 9F Higashitenma building, 1-7-17 Higashitenma, Kita-ku, Osaka, Osaka 530-0044, Japan |
| Tel | 06-6135-5200 |
| mterashima@miura-cl.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045914 |